About Teva Pharmaceuticals Usa, Inc.
Teva Pharmaceutical Industries is part of the no-name world of generic pharmaceuticals. The company makes affordable medicines and benefit from innovations to improve their health, including generics, specialty medicines and biopharmaceuticals, improving the lives of patients. Headquartered in Israel, Teva is a generic medicines maker, using its portfolio of more than 1,800 molecules to produce generics in nearly every therapeutic area. In specialty medicines, Teva is making innovative treatments for disorders of the central nervous system (CNS) as well as respiratory products. The company operates in three segments: North America, Europe, and International Markets. Around half of the company's total sales were generated from the North America.
Teva operates its business through three segments: North America (accounts more than 50% of company's revenue), Europe (about 30% of revenue) and International Markets (nearly 15% of revenue).
The North America segment includes the United States and Canada. Its specialty portfolio has an established presence in central nervous system (CNS) medicines.
Europe segment includes the European Union and certain other European countries. Its specialty portfolio focuses on three main areas: CNS and pain, respiratory and oncology.
The International Markets segment includes all countries in which the company operate other than those in its North America and Europe segments. These markets comprise more than 35 countries, covering a substantial portion of the global pharmaceutical market. Its specialty portfolio in International Markets focuses on three main areas: CNS and pain, respiratory and oncology.
Generic medicines produced by Teva include chemical and therapeutic versions of tablets, capsules, injectables, inhalants, liquids, ointments, and creams. Specialty medicines include Copaxone, Ajovy, Austedo, Bendeka and Treanda , ProAir (ProAir HFA ProAir Digihaler, and ProAir RespiClick), QVAR (QVAR and QVAR RediHaler), Cinqair/Cinqaero, AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler and Braltus. In addition to focusing on therapeutic areas of CNS and respiratory medicines, Teva provides specialty medicines in oncology and selected other areas.
The company also supplies active pharmaceutical ingredients (APIs), the essential raw materials used in drug manufacturing.
The company has a collaboration with Takeda Pharmaceutical, through which Takeda can commercialize Teva's treatments for Parkinson's disease (Copaxone) and multiple sclerosis (Azilect) in Japan.
Teva holds a portfolio of more than 1,800 molecules; it produces some 85 billion tablets and capsules annually at its 90 manufacturing facilities.
Teva has 90 manufacturing and R&D facilities in more than 60 countries. The company is structured into three geographic segments -- North America (which accounts for more than half of total sales), Europe (less than 30% of sales), and International Markets (about 15% of sales).
Its primary manufacturing technologies, solid dosage forms, injectables and blow-fill-seal, are available in North America, Europe, Latin America and Israel. The manufacturing sites located in Israel, Germany, Hungary, Croatia, Bulgaria, India, Spain, Poland and the Czech Republic make up the majority of its production capacity.
Sales and Marketing
Teva's generic sales in the United States are made to directly to retail drug chains, mail order distributors and wholesaler.
In North America, the group participates in pharmaceutical conferences and advertises in professional journals and on pharmacy websites.
The company's advertising costs for the years 2019, 2018 and 2017 were $213 million, $256 million and $318 million, respectively.
Teva's revenue has been declining since 2017. Its net income suffered consecutive net losses since 2017.
Teva's revenues in 2019 were $16.9 million, a decrease of 8% in US dollar, or 5% in local currency terms, compared to 2018, mainly due to generic competition to COPAXONE, a decline in revenues from its US generics business, BENDEKA/TREANDA and Japan, partially offset by higher revenues from AUSTEDO, AJOVY and QVAR in the United States.
Net loss attributable to Teva was $999 million in 2019, compared to a net loss of $2.2 million in 2018.
Teva ended 2018 with $2 billion in net cash, 11% more than what it had at the end of 2018. Operating activities provided $748 million and investing activities provided another $1.4 billion, while financing activities (primarily the repayment of liabilities) used $1.9 billion.
In December 2017, Teva announced a comprehensive two-year restructuring plan intended to reduce its cost base by $3 billion, unify and simplify its organization and improve business performance, profitability, cash flow generation and productivity. This plan achieved its goals, including a total cost base reduction of $3 billion by the end of 2019. The company is continuing to evaluate opportunities to further optimize its manufacturing and supply network to achieve additional operational efficiencies.
All of the company's R&D activities are concentrated under one global group with overall responsibility for generics, specialty and biologics, enabling better focus and efficiency.
A strong focus for Teva is the development of new generic medicines. Teva develops generic products for the United States, Europe, and its International Markets segment. The company's focus is on developing complex formulations with complex technologies, which have higher barriers to entry. Generic R&D activities, which are carried out in development centers located around the world, include product formulation, analytical method development, stability testing, management of bioequivalence, bio-analytical studies, other clinical studies and registration of generic drugs in all of the markets where Teva operates.
400 Interpace Pkwy Ste A1
Parsippany, NJ 07054-1119
Phone: 1 (215) 591-3000
Employer Type: Publicly Owned
Strategic Associate To The President Americas Generics: Brandon Boyd
CNS Sales Representative (Presidents Club Winner): Kevin Kusmider
Chief Operating Officer: Douglas Stateler
Employees (This Location): 350
Employees (All Locations): 1,025
New York, NY
North Wales, PA